Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1/2010

01-12-2010 | Original Paper

Selectins as Mediators of Lung Metastasis

Authors: Heinz Läubli, Lubor Borsig

Published in: Cancer Microenvironment | Issue 1/2010

Login to get access

Abstract

Lung metastasis remains the major cause of cancer related mortality in patients with breast, gastrointestinal, sarcoma, melanoma and kidney cancer. Here we characterize the expression of selectins during metastatic lung colonization and analyzed their function in the formation of pulmonary metastasis. E-selectin, together with VCAM-1, were detected 6 h after the microvascular arrest of tumor cells indicating an inflammatory activation of the local endothelial cells. No E-selectin expression was detected in pre-metastatic lungs of mice carrying primary tumors. P- and L-selectin were present during initiating steps of lung colonization and correlated with the recruitment of platelets and leukocytes to metastatic tumor cells. Experimental metastasis was significantly reduced in the absence of P- or L-selectin while no attenuation of metastasis was observed in E-selectin-deficient mice. Collectively, selectins are upregulated within the metastatic microenvironment of tumor cells and the formation of a permissive metastatic microenvironment is facilitated by P- and L-selectin mediated interactions between tumor cells and blood components. E-selectin does not affect metastatic initiation in the lung tissue and its expression rather indicates a local activation of lung microvascular endothelial cells.
Appendix
Available only for authorised users
Literature
1.
2.
Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895–904CrossRefPubMed
3.
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572CrossRefPubMed
4.
5.
6.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458CrossRefPubMed
7.
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252CrossRefPubMed
8.
Husemann Y, Geigl JB, Schubert F et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68CrossRefPubMed
9.
Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549CrossRefPubMed
10.
Gupta GP, Nguyen DX, Chiang AC et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770CrossRefPubMed
11.
Bos PD, Zhang XH, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009CrossRefPubMed
12.
Cines DB, Pollak ES, Buck CA et al (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527–3561PubMed
13.
Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM (2000) Interactions between cancer cells and the endothelium in metastasis. J Pathol 190:310–329CrossRefPubMed
14.
15.
Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355–362CrossRefPubMed
16.
Laubli H, Borsig L (2009) Heparins attenuate cancer metastasis: are selectins the link? Cancer Invest 27:474–481CrossRefPubMed
17.
Nieswandt B, Hafner M, Echtenacher B, Mannel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed
18.
Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed
19.
Borsig L, Wong R, Hynes RO, Varki NM, Varki A (2002) Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 99:2193–2198CrossRefPubMed
20.
Liang S, Sharma A, Peng HH, Robertson G, Dong C (2007) Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 67:5814–5820CrossRefPubMed
21.
Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L (2006) L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 66:1536–1542CrossRefPubMed
22.
Kim S, Takahashi H, Lin WW et al (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102–106CrossRefPubMed
23.
Laubli H, Spanaus KS, Borsig L (2009) Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 114:4583–4591CrossRefPubMed
24.
Borsig L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98:3352–3357CrossRefPubMed
25.
Stevenson JL, Choi SH, Varki A (2005) Differential metastasis inhibition by clinically relevant levels of heparins–correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11:7003–7011CrossRefPubMed
26.
Hostettler N, Naggi A, Torri G et al (2007) P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 21:3562–3572CrossRefPubMed
27.
McEver RP (2002) Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 14:581–586CrossRefPubMed
28.
Auguste P, Fallavollita L, Wang N et al (2007) The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 170:1781–1792CrossRefPubMed
29.
Scamuffa N, Siegfried G, Bontemps Y et al (2008) Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 118:352–363CrossRefPubMed
30.
Vidal-Vanaclocha F, Fantuzzi G, Mendoza L et al (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97:734–739CrossRefPubMed
31.
Brodt P, Fallavollita L, Bresalier RS et al (1997) Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 71:612–619CrossRefPubMed
32.
Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I (1996) Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 183:581–587CrossRefPubMed
33.
Khatib AM, Auguste P, Fallavollita L et al (2005) Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 167:749–759PubMed
34.
Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827CrossRefPubMed
35.
Hiratsuka S, Nakamura K, Iwai S et al (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300CrossRefPubMed
36.
Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369–1375CrossRefPubMed
37.
Erler JT, Bennewith KL, Cox TR et al (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35–44CrossRefPubMed
38.
Garcia J, Callewaert N, Borsig L (2007) P-selectin mediates metastatic progression through binding to sulfatides on carcinoma cells. Glycobiology 17:185–196CrossRefPubMed
39.
Ludwig RJ, Boehme B, Podda M et al (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64:2743–2750CrossRefPubMed
40.
Mannori G, Santoro D, Carter L et al (1997) Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol 151:233–243PubMed
41.
Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P (2002) Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 62:5393–5398PubMed
42.
Laferriere J, Houle F, Taher MM, Valerie K, Huot J (2001) Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem 276:33762–33772CrossRefPubMed
43.
Tremblay PL, Auger FA, Huot J (2006) Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases. Oncogene
44.
Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R (2005) CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 65:5812–5817CrossRefPubMed
45.
Burdick MM, McCaffery JM, Kim YS, Bochner BS, Konstantopoulos K (2003) Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. Am J Physiol Cell Physiol 284:C977–C987PubMed
46.
Fukuda MN, Ohyama C, Lowitz K et al (2000) A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 60:450–456PubMed
47.
Camerer E, Qazi AA, Duong DN et al (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401CrossRefPubMed
48.
Gasic GJ, Tuszynski GP, Gorelik E (1986) Interaction of the hemostatic and immune systems in the metastatic spread of tumor cells. Int Rev Exp Pathol 29:173–212PubMed
49.
Borsig L (2008) The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 8:1247–1255CrossRefPubMed
50.
Ludwig RJ, Alban S, Bistrian R et al (2006) The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 95:535–540PubMed
51.
Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113CrossRefPubMed
52.
Qian B, Deng Y, Im JH et al (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4:e6562CrossRefPubMed
Metadata
Title
Selectins as Mediators of Lung Metastasis
Authors
Heinz Läubli
Lubor Borsig
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2010
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-010-0043-6

Other articles of this Issue 1/2010

Cancer Microenvironment 1/2010 Go to the issue

Review Paper

The Tumor Microenvironment in Colorectal Carcinogenesis

Original Paper

Mammographic Density and Matrix Metalloproteinases in Breast Tissue

Review Paper

T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets

Review Paper

Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer

Review Paper

The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade

Original Paper

VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits